Rigaku Pharmaceutical Technologies Showcase Globe IconRigaku Global Website Email Iconpharma@rigaku.com
Rigaku Pharmaceutical Technologies Showcase Globe IconRigaku Global Website Email Iconpharma@rigaku.com Phone Icon

      The Pharma Lab Show: The Role of Polymorphism in the Future of Pharma

      Simon Bates, Ph. D.

       

      Part 2. Catch up on Part 1 of the polymorph roundtable discussion here!

      Join Simon Bates, our host for this episode and VP of Science and Technology at Rigaku Americas Corporation, as he engages in a lively roundtable discussion with six industry experts on the future of polymorphs and current challenges. In this 2nd part of the round table event, our distinguished guests discuss the impact and challenges of polymorphism. You’ll hear from these life science and pharmaceutical experts:

      • Eyal Barash, Life Sciences Patent Attorney and Founder at Barash Law
      • Steve Byrn, Professor and Dept. Head at Purdue University
      • Mansoor Khan, Professor and Vice Dean, Presidential Impact Fellow, Rangel College of Pharmacy, Texas A&M University
      • Ken Morris, University Professor, Director Lachman Institute for Pharmaceutical Analysis, Long Island University
      • Ann Newman, Solid-State and Pharmaceutical Consultant at Seventh Street Development Group
      • Raj Suryanarayanan, Professor and William and Mildred Peters Endowed Chair at University of Minnesota

      We talked about:

      • Stunning evolutionary advances in the field of pharmaceutical polymorphs.
      • Bringing in computational and big data solutions. 
      • Challenges in patentability for smaller companies. 
      • A bright future in polymorphism.

      Key takeaways from this episode

      • The physical form, and specifically the polymorphic form, will continue to be important, and I think that the analytical techniques will be getting better and better.” — Raj Suryanarayanan
      • We're discovering so many new things in pharmaceutics.” — Ann Newman
      • “The use of big data for pharma structure solutions is really an underdeveloped area.” — Ken Morris
      • ”There are a lot of efforts in COVID these days, so what is polymorphism? What can polymorphism do here?” — Mansoor Khan
      • In the United States, a generic company can go on the market with a different polymorph, if they can show it's bio equivalent.” — Eyal Barash

      Check out more information on Rigaku's work with polymorphs and why understanding polymorphism and their impact are important. 
      For more insights into the pharmaceutical industry, subscribe to the show on Apple Podcasts, Spotify, or wherever podcasts are found.
      Check out the Rigaku Pharmaceutical Technologies Showcase for more information on Rigaku's commitment to the pharmaceutical industry

      …
      Simon Bates, Ph. D.
      Simon Bates serves customers as the VP of Science and Technology with Rigaku Americas. Simon Bates received his PhD in Applied Physics from the University of Hull, utilizing Neutron diffraction to study the magnetic properties of rare earth materials. The neutron diffraction work was performed at the Institute Laue Langevin in Grenoble. For his postdoctoral work in the Dept. of Physics at the University of Edinburgh, Simon helped design and build high-resolution triple axis X-ray diffraction systems for the study of solid-state phase transformations. Simon continued his work on high resolution X-ray diffraction systems at both Philips NV and Bede Scientific where he was focused on the development of X-ray diffraction and X-ray reflectivity methods for the measurement and modeling of advanced materials. Before moving to Rigaku, Simon spent the last 15 years working in contract research organizations (SSCI and Triclinic Labs) studying solid state pharmaceutical materials. In particular, he was directly involved in the development of advanced characterization methods for formulated pharmaceutical products based on the analysis of structure (crystalline, non-crystalline, meso-phase, polymorph, salt, co-crystal..), microstructure (texture, strain, crystal size, habit..) and their functional relationships in the solid state. Simon also holds an appointment as an Adjunct Professor at LIU in the Division of Pharmaceutical Sciences where he helps teach a graduate course on solid state materials analysis.